Pfizer: Rapid Education on Drug – Drug Interactions in Covid 19 Outpatient Treatment

Application Due Date: January 10, 2023

Specific Area of Interest: Through this RFP it is our intent to support rapidly developed and deployed educational programs that address potential knowledge gaps related to drug-drug interactions (DDIs) in COVID-19 outpatient treatment and are designed to help achieve the following goals:

  • Improve ability to assess patients for potential DDIs prior to treatment
  • Increase confidence with managing DDIs (monitoring parameters, dose adjustments, therapy adjustments, etc.) and potential adverse events
  • Increase awareness of tools available to manage DDIs for outpatient COVID-19 therapeutics
  • Increase awareness of national COVID-19 treatment guidelines (e.g., NIH, IDSA, etc.) for COVID-19 in non-hospitalized patients


For additional information please visit the REAP webpage @